# Metronidazole

## Metronidazole inj 500mg/100mL

| TAH Drug Code      | [IMETR5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IMETR5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment for severe infections caused by anaerobic bacteria sensitive to Metronidazole and infections caused by Bacteroides fragilis resistant to Clindamycin, Chloramphenicol, and Penicillin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Intra-abdominal infection: IV: 500 mg every 8 to 12 hours as part of an appropriate combination regimen. Duration of therapy is 4 to 5 days following adequate source control. For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days; for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient. Intracranial abscess (brain abscess, intracranial epidural abscess): IV: 7.5 mg/kg (usually 500 mg) every 6 to 8 hours (maximum dose: 4 g/day) for 6 to 8 weeks in combination with other appropriate antimicrobial therapy. Pneumonia, aspiration (alternative agent): IV: 500 mg 3 times daily in combination with an appropriate beta-lactam (eg, oral amoxicillin, IV penicillin, or an IV third-generation cephalosporin) for 7 days. Skin and soft tissue infection: Necrotizing infection (as a component of an appropriate combination regimen) (alternative agent): IV: 500 mg every 6 hours. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours. Surgical site infection, incisional (eg, intestinal or GU tract; axilla or perineum), warranting anaerobic coverage: IV: 500 mg every 8 hours in combination with other appropriate agents. Duration depends on severity, need for debridement, and clinical response. Surgical prophylaxis: IV: 500 mg within 60 minutes prior to surgical incision in combination with other antibiotics. Considered a recommended agent for select procedures involving the GI tract, urologic tract, or head and neck. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to metronidazole, nitroimidazole derivatives, or any component of the formulation. Patients with blood disorders (may experience leukopenia). Patients with brain or spinal cord diseases (may exhibit central nervous system symptoms). During the first trimester of pregnancy in patients with trichomoniasis (with the exception of Likmez). Use of disulfiram within the past 2 weeks. Use of alcohol or propylene glycol-containing products during therapy or within 3 days of therapy discontinuation. Cockayne syndrome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | >10%: Gastrointestinal: Nausea (10% to 12%) Genitourinary: Vaginitis (15%) Nervous system: Headache (18%) 1% to 10%: Gastrointestinal: Abdominal pain (4%), diarrhea (4%), metallic taste (9%), xerostomia (2%) Genitourinary: Dysmenorrhea (3%), genital pruritus (5%), urinary tract infection (2%), urine abnormality (3%) Infection: Bacterial infection (7%), candidiasis (3%) Nervous system: Dizziness (4%) Respiratory: Flu-like symptoms (6%), pharyngitis (3%), rhinitis (4%), sinusitis (3%), upper respiratory tract infection (4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/metronidazole-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## Metrozole 250mg

| TAH Drug Code      | [OMETR](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMETR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Vaginitis caused by Trichomonas. Amebiasis & metronidazole-susceptible anaerobic infection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Dosing             | (仿單) Adults: Anaerobic infections: 7.5 mg/kg Q6H for 7 days (maximum 1 g/dose; 4 g/day).Helicobacter pylori: 500 mg orally Q8H in combination with bismuth and other antibiotics for 1-2 weeks. Amebiasis: 500-700 mg orally Q8H for 5-7 days. Trichomoniasis: 2 g orally as a single dose, 1 g Q12H for 1 day or 250 mg Q8H for 7 days. Dracunculiasis: 250 mg Q8H for 10 days. Children: Anaerobic infections:7.5 mg/kg Q6H or 10 mg/kg Q8H. Amebiasis: 11.6-16.7 mg/kg Q8H for 10 days. Trichomoniasis: 5 mg/kg Q8H for 7 days. Dracunculiasis: 8.3 mg/kg (max 250 mg/dose) Q8H for 10 days. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | (1) Patients who have had an allergic reaction to Metronidazole or other Nitroimidazole derivatives. (2) Patients with blood disorders (may exhibit symptoms of leukopenia). (3) Patients with brain or spinal cord diseases (may show central nervous system symptoms). (4) Women within the first three months of pregnancy.                                                                                                                                                                                                                                                                    |
| Adverse Effects    | GI disturbances; peripheral neuropathy; drowsiness; leukopenia; rarely, skin reactions, darkening of urine, anaphylaxis, encephalopathy. Gastrointestinal: Abdominal discomfort (7%), Loss of appetite, Metallic taste, Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% ), Headache (tablets, 15% to 18%; vaginal gel, 5% ), Peripheral neuropathy Reproductive: Candida infection of genital region, Symptomatic cervicitis/vaginitis (10%), Vaginal discharge (12%) Other: Drug interaction with alcohol, Disulfiram-like reaction            |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Hold Breast Feeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/metronidazole-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

